-
Je něco špatně v tomto záznamu ?
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
A. Larocca, R. Mina, M. Offidani, AM. Liberati, A. Ledda, F. Patriarca, A. Evangelista, S. Spada, G. Benevolo, D. Oddolo, V. Innao, C. Cangiolosi, A. Bernardini, P. Musto, V. Amico, V. Fraticelli, L. Paris, N. Giuliani, AP. Falcone, R. Zambello,...
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, randomizované kontrolované studie
NLK
Directory of Open Access Journals
od 1994
Free Medical Journals
od 1994
Freely Accessible Science Journals
od 1994
PubMed Central
od 2009
Europe PubMed Central
od 2009
Open Access Digital Library
od 1994-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1996
- MeSH
- bortezomib * terapeutické užití MeSH
- dexamethason * terapeutické užití MeSH
- lenalidomid * terapeutické užití MeSH
- lidé MeSH
- melfalan * terapeutické užití MeSH
- mnohočetný myelom * diagnóza farmakoterapie MeSH
- prednison * terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment for newly diagnosed MM, particularly in patients with high-risk cytogenetics [del(17p), t(4;14) or t(14;16)]. We pooled together data from patients with newly diagnosed MM treated with VMP or Rd induction followed by lenalidomide maintenance 10 mg (Rd-R) enrolled in the GIMEMA-MM-03-05 and EMN01 trials, to evaluate the efficacy of these treatments in different subgroups of patients, focusing on those with standard- and high-risk cytogenetics. Overall, 474 patients were analyzed (VMP: 257 patients; Rd-R: 217 patients). No differences in progression-free survival (hazard ratio=0.96) and overall survival (hazard ratio=1.08) were observed between standard-risk patients treated with VMP or Rd-R, whereas among the high-risk patients, the probabilities of progression (hazard ratio=0.54) and death (hazard ratio=0.73) were lower in the patients treated with VMP than in those treated with Rd-R. In particular, standard-risk patients >75 years benefited less from VMP than from Rd-R (hazard ratio for progression-free survival=0.96; hazard ratio for overall survival=1.81). In this non-randomized analysis, VMP and Rd-R were equally effective in younger (≤75 years), standard-risk patients, while older ones (>75 years) benefited more from Rd-R. In high-risk patients, VMP improved progression-free survival and overall survival irrespective of age. The source trials are registered at ClinicalTrials.gov (NCT01063179 and NCT01093196).
AO Villa Sofia Cervello Divisione Ematologia 1 UTMO Palermo Italy
Clinica di Ematologia AOU Ospedali Riuniti di Ancona Ancona Italy
Department of Hematooncology University Hospital Ostrava Ostrava Czech Republic
Department of Medicine and Surgery University of Parma Parma Italy
DH Ematologico AO S Pio Benevento Italy
Ematologia CTMO Ospedale A Businco Cagliari Italy
Ematologia IRCCS Casa Sollievo della Sofferenza Hospita San Giovanni Rotondo Italy
Faculty of Medicine University of Ostrava Ostrava Czech Republic
Fondazione Giovanni Paolo 2 Unità Operativa Complessa di Oncoematologia Campobasso Italy
Hematology Città della Salute e della Scienza Torino Italy
Hematology Fondazione IRCCS Istituto Nazionale Tumori Milan Italy
Padova University School of Medicine Hematology and Clinical Immunology Padova Italy
U O C Ematologia AOU G Martino Messina Italy
Udine University Hospital DAME University of Udine Udine Italy
Università degli Studi di Perugia Azienda Ospedaliera Santa Maria Terni Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21020653
- 003
- CZ-PrNML
- 005
- 20210830102253.0
- 007
- ta
- 008
- 210728s2020 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3324/haematol.2019.220657 $2 doi
- 035 __
- $a (PubMed)31248973
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Larocca, Alessandra $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy alelarocca@hotmail.com
- 245 10
- $a First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials / $c A. Larocca, R. Mina, M. Offidani, AM. Liberati, A. Ledda, F. Patriarca, A. Evangelista, S. Spada, G. Benevolo, D. Oddolo, V. Innao, C. Cangiolosi, A. Bernardini, P. Musto, V. Amico, V. Fraticelli, L. Paris, N. Giuliani, AP. Falcone, R. Zambello, L. De Paoli, A. Romano, A. Palumbo, V. Montefusco, R. Hájek, M. Boccadoro, S. Bringhen
- 520 9_
- $a Bortezomib-melphalan-prednisone (VMP) and continuous lenalidomide-dexamethasone (Rd) represent the standard treatment of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). To date, no randomized trial has compared VMP to Rd, and there is no evidence of the optimal treatment for newly diagnosed MM, particularly in patients with high-risk cytogenetics [del(17p), t(4;14) or t(14;16)]. We pooled together data from patients with newly diagnosed MM treated with VMP or Rd induction followed by lenalidomide maintenance 10 mg (Rd-R) enrolled in the GIMEMA-MM-03-05 and EMN01 trials, to evaluate the efficacy of these treatments in different subgroups of patients, focusing on those with standard- and high-risk cytogenetics. Overall, 474 patients were analyzed (VMP: 257 patients; Rd-R: 217 patients). No differences in progression-free survival (hazard ratio=0.96) and overall survival (hazard ratio=1.08) were observed between standard-risk patients treated with VMP or Rd-R, whereas among the high-risk patients, the probabilities of progression (hazard ratio=0.54) and death (hazard ratio=0.73) were lower in the patients treated with VMP than in those treated with Rd-R. In particular, standard-risk patients >75 years benefited less from VMP than from Rd-R (hazard ratio for progression-free survival=0.96; hazard ratio for overall survival=1.81). In this non-randomized analysis, VMP and Rd-R were equally effective in younger (≤75 years), standard-risk patients, while older ones (>75 years) benefited more from Rd-R. In high-risk patients, VMP improved progression-free survival and overall survival irrespective of age. The source trials are registered at ClinicalTrials.gov (NCT01063179 and NCT01093196).
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 12
- $a bortezomib $x terapeutické užití $7 D000069286
- 650 12
- $a dexamethason $x terapeutické užití $7 D003907
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a lenalidomid $x terapeutické užití $7 D000077269
- 650 12
- $a melfalan $x terapeutické užití $7 D008558
- 650 12
- $a mnohočetný myelom $x diagnóza $x farmakoterapie $7 D009101
- 650 12
- $a prednison $x terapeutické užití $7 D011241
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Mina, Roberto $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Offidani, Massimo $u Clinica di Ematologia, AOU Ospedali Riuniti di Ancona, Ancona, Italy
- 700 1_
- $a Liberati, Anna Marina $u Università degli Studi di Perugia, Azienda Ospedaliera (AO) Santa Maria, Terni, Italy
- 700 1_
- $a Ledda, Antonio $u Ematologia/CTMO Ospedale "A. Businco", Cagliari, Italy
- 700 1_
- $a Patriarca, Francesca $u Udine University Hospital, DAME, University of Udine, Udine, Italy
- 700 1_
- $a Evangelista, Andrea $u Unit of Clinical Epidemiology, AOU Città della Salute e della Scienza di Torino e CPO, Piemonte, Torino, Italy
- 700 1_
- $a Spada, Stefano $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Benevolo, Giulia $u Hematology, Città della Salute e della Scienza, Torino, Italy
- 700 1_
- $a Oddolo, Daniela $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Innao, Vanessa $u U.O.C. Ematologia AOU G. Martino, Messina, Italy
- 700 1_
- $a Cangiolosi, Clotilde $u AO Villa Sofia-Cervello, Divisione Ematologia I UTMO, Palermo, Italy
- 700 1_
- $a Bernardini, Annalisa $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Musto, Pellegrino $u Unit of Haematology and Stem Cell Transplantation, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
- 700 1_
- $a Amico, Valeria $u DH-Ematologico AO "S.Pio", Benevento, Italy
- 700 1_
- $a Fraticelli, Vincenzo $u Fondazione "Giovanni Paolo II", Unità Operativa Complessa di Oncoematologia, Campobasso, Italy
- 700 1_
- $a Paris, Laura $u Hematology and Bone Marrow Transplant Unit, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy
- 700 1_
- $a Giuliani, Nicola $u Department of Medicine and Surgery, University of Parma, Parma, Italy
- 700 1_
- $a Falcone, Antonietta Pia $u Ematologia, IRCCS "Casa Sollievo della Sofferenza" Hospita, San Giovanni Rotondo, Italy
- 700 1_
- $a Zambello, Renato $u Padova University School of Medicine, Hematology and Clinical Immunology, Padova, Italy
- 700 1_
- $a De Paoli, Lorenzo $u Università del Piemonte Orientale A. Avogadro, Novara, Italy
- 700 1_
- $a Romano, Alessandra $u Division of Hematology, AOU Policlinico, Department of Surgery and Medical Specialties, University of Catania, Italy
- 700 1_
- $a Palumbo, Antonio $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Montefusco, Vittorio $u Hematology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
- 700 1_
- $a Hájek, Roman $u Department of Hematooncology University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Boccadoro, Mario $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Bringhen, Sara $u Myeloma Unit, Division of Hematology, University of Torino, Azienda-Ospedaliero Universitaria (AOU) Città della Salute e della Scienza di Torino, Torino, Italy
- 773 0_
- $w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 105, č. 4 (2020), s. 1074-1080
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31248973 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830102254 $b ABA008
- 999 __
- $a ok $b bmc $g 1691263 $s 1141099
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 105 $c 4 $d 1074-1080 $e 20190627 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
- LZP __
- $a Pubmed-20210728
